The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III locally advanced non-small cell lung cancer patients.
 
Yoshitaka Zenke
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; MSD (Inst); Novartis; Pfizer
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Nippon Kayaku; Nitto Denko; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst)
 
Shingo Miyamoto
No Relationships to Disclose
 
Takuma Imakita
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical
 
Tetsuya Mitsudomi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Hiromi Aono
No Relationships to Disclose
 
Ryota Ushio
No Relationships to Disclose
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Roche
Research Funding - Nippon Boehringer Ingelheim
 
Saori Takata
No Relationships to Disclose
 
Mika Nakao
No Relationships to Disclose
 
Satoshi Hara
No Relationships to Disclose
 
Motoko Tachihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Akimasa Sekine
No Relationships to Disclose
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Ryo Toyozawa
Honoraria - Bristol-Myers Squibb; MSD; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Pfizer (Inst); Takeda (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo